NEW YORK (GenomeWeb News) – Indian biotech services company Jubilant Biosys has entered a co-marketing agreement with DiscoveRx to screen potential drug compounds, Jubilant said yesterday.

The agreement will enable Jubilant’s pharmaceutical customers to use DiscoveRx services such as the PathHunter and CampHunter cell lines and chemiluminescent detection technology.

The agreement will also allow DiscoveRx to offer screening solutions from India, Jubilant said.

Jubilant Biosys, based in Noida with facilities in Bangalore, is a subsidiary of Jubilant Organsys.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.